Duration of triple antithrombotic therapy and clinical outcomes after percutaneous coronary intervention in atrial fibrillation.

Background: Triple antithrombotic therapy (TAT) with aspirin, a P2Y inhibitor, and oral anticoagulation in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) raises concerns about increased bleeding. Regimens incorporating more potent P2Y inhibitors over clopidogrel have not been investigated adequately.

Research Design And Methods: A retrospective observational study was performed on 387 patients with AF receiving TAT for 1 month ( = 236) or ≤1 week ( = 151) after PCI. Major and clinically relevant non-major bleeding and major adverse cardiac and cerebrovascular events (MACCE) were assessed up to 30 days post-procedure.

Results: Bleeding was less frequent with ≤1 week versus 1 month of TAT (3.3 vs 9.3%;  = 0.025) while MACCE were similar (4.6 vs 4.7%;  = 0.998). No differences in bleeding or MACCE were observed between ticagrelor/prasugrel and clopidogrel regimens. For patients receiving ≤1 week of TAT, no excess of MACCE was seen in the subgroup given no further aspirin post-PCI compared with those given aspirin for up to 1 week (3.6 vs 5.2%).

Conclusions: TAT post-PCI for ≤1 week was associated with less bleeding despite greater use of ticagrelor/prasugrel but similar MACCE versus 1-month TAT. These findings support further studies on safety and efficacy of dual therapy with ticagrelor/prasugrel immediately after PCI.